| First Author | Wang L | Year | 2013 |
| Journal | Diabetes | Volume | 62 |
| Issue | 12 | Pages | 4122-31 |
| PubMed ID | 23990359 | Mgi Jnum | J:208926 |
| Mgi Id | MGI:5565401 | Doi | 10.2337/db13-0518 |
| Citation | Wang L, et al. (2013) PPARalpha and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders. Diabetes 62(12):4122-31 |
| abstractText | Erythropoietin (EPO) has shown beneficial effects in the regulation of obesity and metabolic syndrome; however, the detailed mechanism is still largely unknown. Here, we created mice with adipocyte-specific deletion of EPO receptor. These mice exhibited obesity and decreased glucose tolerance and insulin sensitivity, especially when fed a high-fat diet. Moreover, EPO increased oxidative metabolism, fatty acid oxidation, and key metabolic genes in adipocytes and in white adipose tissue from diet-induced obese wild-type mice. Increased metabolic activity by EPO is associated with induction of brown fat-like features in white adipocytes, as demonstrated by increases in brown fat gene expression, mitochondrial content, and uncoupled respiration. Peroxisome proliferator-activated receptor (PPAR)alpha was found to mediate EPO activity because a PPARalpha antagonist impaired EPO-mediated induction of brown fat-like gene expression and uncoupled respiration. PPARalpha also cooperates with Sirt1 activated by EPO through modulating the NAD+ level to regulate metabolic activity. PPARalpha targets, including PPARgamma coactivator 1alpha, uncoupling protein 1, and carnitine palmitoyltransferase 1alpha, were increased by EPO but impaired by Sirt1 knockdown. Sirt1 knockdown also attenuated adipose response to EPO. Collectively, EPO, as a novel regulator of adipose energy homeostasis via these metabolism coregulators, provides a potential therapeutic strategy to protect against obesity and metabolic disorders. |
